Omarigliptin

奥玛格列汀

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameOmarigliptin
Drug Alias Nameomarigliptina奥格列汀omarigliptineomarigliptinumMarizev +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes MellitusRenal Insufficiency, Chronic
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2015/09/28
Country/TerritoryJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme Corp
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsDiabetes MellitusRenal Insufficiency, Chronic

Other Information

ATC CodeA10BH
Related LinksWikipediaDrugBankKEGG